Nasdaq:BIIBPublished
Biogen’s Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease
Diranersen slowed clinical decline by 38% on CDR-SB at two years (Week 96) with the 60 mg twice-yearly regimen, corresponding to a 1.09-point treatment difference Greater slowing of clinical decline across 5 of 6 measures at two years compared with 18 months (Week 76) in the 60…